Latest hypoglycemia Stories
PHILADELPHIA, June 11, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced results from two Phase II studies of their investigational novel basal insulin analog, LY2605541. Results of the type 1 diabetes study showed that LY2605541 was associated with greater improvements of glycemic control (lowering blood sugar levels) than insulin glargine. In the type 2 diabetes study, the primary measure showed that LY2605541 and insulin glargine had...
--JDRF-funded research demonstrates the feasibility of a wearable artificial pancreas to control blood sugar levels in first outpatient study-- NEW YORK, June 11, 2012 /PRNewswire-USNewswire/ --JDRF, a global leader in type 1 diabetes(T1D) research, is pleased to announce that an outpatient study being conducted at multiple academic institutions has demonstrated the safety and feasibility of artificial pancreas (AP) device testing on an ambulatory basis. The research, funded by...
PHILADELPHIA, June 9, 2012 /PRNewswire/ -- Ultra long-acting insulin degludec, an investigational insulin being developed by Novo Nordisk, significantly reduced the rate of hypoglycemia* at night in adults with type 2 diabetes while obtaining equivalent improvement in glucose control compared with insulin glargine over a 52-week period. This phase 3a study was presented today at the 72nd Scientific Sessions of the American Diabetes Association (ADA). To view the multimedia assets...
PHILADELPHIA, June 9, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) presented results from five Phase 3 clinical studies evaluating canagliflozin in monotherapy and in add-on combination use showing that canagliflozin provided substantial and sustained glycemic improvements in adult patients with type 2 diabetes, and was generally well tolerated. In two of these studies comparing canagliflozin to current standard treatments, sitagliptin and glimepiride,...
PHILADELPHIA, June 9, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the presentation of two posters at the 72nd Scientific Sessions of the American Diabetes Association (ADA) highlighting its research on improved treatment options for both the multiple daily injection therapy and continuous subcutaneous insulin infusion markets. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO) Presenters will be available to discuss the posters at...
DANBURY, Conn., June 8, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) and Aegis Therapeutics, LLC (Aegis) today announced a partnership providing Biodel an exclusive worldwide license to Aegis' proprietary ProTek® and Intravail® technologies for the development and commercialization of pharmaceutical formulations of glucagon. ProTek® protein stabilization technology comprises the use of proprietary GRAS excipients that prevent aggregation of proteins and peptides thereby...
-- Partnership Announced Between Leaders of Artificial Pancreas Research and Development to Develop Novel Redundant Sensor System to Help Improve Glucose Control for People with Diabetes -- NEW YORK, June 1, 2012 /PRNewswire-USNewswire/ -- JDRF in collaboration with the Helmsley Charitable Trust (HCT) announced today a partnership with Medtronic, Inc. (NYSE:MDT), a leader in artificial pancreas research and development. The JDRF-HCT Sensor Initiative aims to advance continuous...
RIDGEFIELD, Conn. and INDIANAPOLIS, May 29, 2012 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced they have received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of Jentadueto® (linagliptin/metformin hydrochloride) tablets, a medicine combining the DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta® tablets, marketed under the trade name Trajenta® in Europe) and...
PRINCETON, N.J., May 22, 2012 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that the U.S. Food and Drug Administration (FDA) has approved Levemir(®) (insulin detemir [rDNA origin] injection) for use in children ages two to five years with type 1 diabetes. With the expansion of its pediatric indication, Levemir(®) is now available for type 1 diabetes patients from age two through adulthood and adult patients with type 2 diabetes. To view the...
GREENVILLE, S.C., May 22, 2012 /PRNewswire/ -- Glytec, LLC, headquartered in Greenville, SC, announced today that its Glucommander(TM) 2.0 Enterprise software has been cleared by the FDA for pediatric use, ages 2 - 17. Glytec's Glucommander was the first insulin dosing software to be cleared for adult (ages 18+) intravenous use; it is the only company to achieve specific clearance for subcutaneous use, and now it is the only company cleared to offer this technology to hospitals caring...
Latest hypoglycemia Reference Libraries
Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...
